Drug Trial Radar · NCT06109779
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
760
Actual
Start
Dec 4, 2023
Primary completion
Jan 2, 2029
Study completion May 3, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.
Conditions
- Biliary Tract Cancer
Interventions
RilvegostomigDrug
Rilvegostomig IV (intravenous) Q3W
PlaceboDrug
Placebo IV (intravenous) Q3W
CapecitabineDrug
Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
Gemcitabine/CisplatinDrug
Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
S-1 [Tegafur/Oteracil/gimeracil]Drug
S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence free survival (RFS) for Arm A vs. Arm BTime frame: Approximately 5 years
Locations
176 sites in 21 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Phoenix, Arizona
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
Stanford, California
Research Site
Aurora, Colorado
Research Site
Littleton, Colorado
Research Site
Washington D.C., District of Columbia
Research Site
Jacksonville, Florida
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Iowa City, Iowa
Research Site
Kansas City, Kansas
Research Site
Lexington, Kentucky
Research Site
New Orleans, Louisiana
Research Site
Grand Rapids, Michigan
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
Commack, New York
Research Site
Mineola, New York
Research Site
Philadelphia, Pennsylvania
Research Site
Dallas, Texas
Research Site
Camperdown, Australia
Research Site
Clayton, Australia
Research Site
Murdoch, Australia
Research Site
Westmead, Australia
Research Site
Brussels, Belgium
Research Site
Brussels, Belgium
Research Site
Edegem, Belgium
Research Site
Leuven, Belgium
Research Site
Natal, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Santa Maria, Brazil
Research Site
Santo André, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Vitória, Brazil
Research Site
Vancouver, British Columbia, Canada
Research Site
Halifax, Nova Scotia, Canada
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.